Back to Search
Start Over
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.
- Source :
-
Leukemia & Lymphoma . Oct2017, Vol. 58 Issue 10, p2310-2318. 9p. - Publication Year :
- 2017
-
Abstract
- Histone deacetylase inhibitors (HDACi) have proven activity in hematologic malignancies, and their FDA approval in multiple myeloma (MM) and T-cell lymphoma highlights the need for further development of this drug class. We investigated AR-42, an oral pan-HDACi, in a first-in-man phase 1 dose escalation clinical trial. Overall, treatment was well tolerated, no DLTs were evident, and the MTD was defined as 40 mg dosed three times weekly for three weeks of a 28-day cycle. One patient each with MM and mantle cell lymphoma demonstrated disease control for 19 and 27 months (ongoing), respectively. Treatment was associated with reduction of serum CD44, a transmembrane glycoprotein associated with steroid and immunomodulatory drug resistance in MM. Our findings indicate that AR-42 is safe and that further investigation of AR-42 in combination regimens for the treatment of patients with lymphoma and MM is warranted. Trial registration:http://clinicaltrials.gov/ct2/show/NCT01129193 [ABSTRACT FROM PUBLISHER]
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 58
- Issue :
- 10
- Database :
- Academic Search Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 123828285
- Full Text :
- https://doi.org/10.1080/10428194.2017.1298751